{"pmid":32487869,"title":"COVID-19 and myocardial injury: is there a role for interleukin-1 inhibition?","text":["COVID-19 and myocardial injury: is there a role for interleukin-1 inhibition?","J Cardiovasc Med (Hagerstown)","Imazio, Massimo","Andreis, Alessandro","De Ferrari, Gaetano Maria","32487869"],"journal":"J Cardiovasc Med (Hagerstown)","authors":["Imazio, Massimo","Andreis, Alessandro","De Ferrari, Gaetano Maria"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32487869","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.2459/JCM.0000000000000998","topics":["Treatment","Mechanism"],"weight":1,"_version_":1668892169450029057,"score":9.490897,"similar":[{"pmid":32399954,"title":"SARS-CoV-2 and myocardial injury: a role for Nox2?","text":["SARS-CoV-2 and myocardial injury: a role for Nox2?","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be complicated by myocardial injury but at-risk patients as well as mechanism of disease are unclear. We gathered data regarding troponin levels in the so far reported SARS-CoV-2 patients and found a large variability in terms of troponin levels, patients with more severe disease, as those treated by ICU, presenting with higher percentage of troponin elevation. However, lack of prospective studies hampers adequate analysis of risk factors of myocardial damage. Previous study demonstrated that Nox2 is up-regulated in pneumonia and closely associated with troponin elevation suggesting Nox2 activation as mechanism eliciting myocardial damage; data in SARS-CoV-2 are still lacking. We hypothesize that SARS-Cov-2 may induce myocardial injury via Nox2-related ROS production and that analysis and eventually targeting Nox2 may be a novel approach to manage SARS-CoV-2.","Intern Emerg Med","Violi, Francesco","Pastori, Daniele","Pignatelli, Pasquale","Cangemi, Roberto","32399954"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be complicated by myocardial injury but at-risk patients as well as mechanism of disease are unclear. We gathered data regarding troponin levels in the so far reported SARS-CoV-2 patients and found a large variability in terms of troponin levels, patients with more severe disease, as those treated by ICU, presenting with higher percentage of troponin elevation. However, lack of prospective studies hampers adequate analysis of risk factors of myocardial damage. Previous study demonstrated that Nox2 is up-regulated in pneumonia and closely associated with troponin elevation suggesting Nox2 activation as mechanism eliciting myocardial damage; data in SARS-CoV-2 are still lacking. We hypothesize that SARS-Cov-2 may induce myocardial injury via Nox2-related ROS production and that analysis and eventually targeting Nox2 may be a novel approach to manage SARS-CoV-2."],"journal":"Intern Emerg Med","authors":["Violi, Francesco","Pastori, Daniele","Pignatelli, Pasquale","Cangemi, Roberto"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32399954","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1007/s11739-020-02348-6","topics":["Mechanism","Treatment"],"weight":1,"_version_":1666714494857904128,"score":51.740337},{"pmid":32118393,"title":"[Myocardial injury in patients with COVID-19 pneumonia].","text":["[Myocardial injury in patients with COVID-19 pneumonia].","Zhonghua Xin Xue Guan Bing Za Zhi","Wei, Z Y","Qian, H Y","32118393"],"journal":"Zhonghua Xin Xue Guan Bing Za Zhi","authors":["Wei, Z Y","Qian, H Y"],"date":"2020-03-03T11:00:00Z","year":2020,"_id":"32118393","source":"PubMed","week":"202010|Mar 02 - Mar 08","doi":"10.3760/cma.j.issn.cn112148-20200220-00106","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138490750894080,"score":45.004692},{"pmid":32499236,"title":"COVID-19 pandemic and troponin: indirect myocardial injury, myocardial inflammation or myocarditis?","text":["COVID-19 pandemic and troponin: indirect myocardial injury, myocardial inflammation or myocarditis?","The initial mechanism for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is the binding of the virus to the membrane-bound form of ACE2, which is mainly expressed in the lung. Since the heart and the vessels also express ACE2, they both could become targets of the virus. However, at present the extent and importance of this potential involvement are unknown. Cardiac troponin levels are significantly higher in patients with more severe infections, patients admitted to intensive care units or in those who have died. In the setting of COVID-19, myocardial injury, defined by an increased troponin level, occurs especially due to non-ischaemic myocardial processes, including severe respiratory infection with hypoxia, sepsis, systemic inflammation, pulmonary thrombosis and embolism, cardiac adrenergic hyperstimulation during cytokine storm syndrome, and myocarditis. At present, there are limited reports on definite diagnosis of myocarditis caused by SARS-CoV-2 in humans and limited demonstration of the virus in the myocardium. In conclusion, although the heart and the vessels are potential targets in COVID-19, there is currently limited evidence on the direct infection of the myocardium by SARS-CoV-2. Additional pathological studies and autopsy series will be very helpful to clarify the potentiality of COVID-19 to directly infect the myocardium and cause myocarditis.","Heart","Imazio, Massimo","Klingel, Karin","Kindermann, Ingrid","Brucato, Antonio","De Rosa, Francesco Giuseppe","Adler, Yehuda","De Ferrari, Gaetano Maria","32499236"],"abstract":["The initial mechanism for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is the binding of the virus to the membrane-bound form of ACE2, which is mainly expressed in the lung. Since the heart and the vessels also express ACE2, they both could become targets of the virus. However, at present the extent and importance of this potential involvement are unknown. Cardiac troponin levels are significantly higher in patients with more severe infections, patients admitted to intensive care units or in those who have died. In the setting of COVID-19, myocardial injury, defined by an increased troponin level, occurs especially due to non-ischaemic myocardial processes, including severe respiratory infection with hypoxia, sepsis, systemic inflammation, pulmonary thrombosis and embolism, cardiac adrenergic hyperstimulation during cytokine storm syndrome, and myocarditis. At present, there are limited reports on definite diagnosis of myocarditis caused by SARS-CoV-2 in humans and limited demonstration of the virus in the myocardium. In conclusion, although the heart and the vessels are potential targets in COVID-19, there is currently limited evidence on the direct infection of the myocardium by SARS-CoV-2. Additional pathological studies and autopsy series will be very helpful to clarify the potentiality of COVID-19 to directly infect the myocardium and cause myocarditis."],"journal":"Heart","authors":["Imazio, Massimo","Klingel, Karin","Kindermann, Ingrid","Brucato, Antonio","De Rosa, Francesco Giuseppe","Adler, Yehuda","De Ferrari, Gaetano Maria"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32499236","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1136/heartjnl-2020-317186","keywords":["acute coronary syndromes","myocarditis","pericardial effusion","thromboembolic pulmonary vascular disease"],"locations":["hypoxia","cytokine"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668890966313926657,"score":45.00177},{"pmid":32504751,"title":"A novel role of nifuroxazide in attenuation of sepsis-associated acute lung and myocardial injuries; role of TLR4/NLPR3/IL-1beta signaling interruption.","text":["A novel role of nifuroxazide in attenuation of sepsis-associated acute lung and myocardial injuries; role of TLR4/NLPR3/IL-1beta signaling interruption.","Acute lung injury (ALI) and the subsequent multi-system organ failure is a serious health problem with devastating impacts on the health care systems. Indeed, the world has been facing an un-preceded situation in the past couple of months following COVID-19 infestation and the associated high-mortality rates mainly attributed to sepsis and the associated multiple organ failures of particular concern; acute respiratory distress syndrome post lung injury. The current study provides evidence on the ameliorative impact of nifuroxazide, and FDA approved antidiarrheal drug in attenuation of lipopolysaccharide (LPS)-induced ALI and myocarditis when administrated either in prophylactic or curative regimens. Nifuroxazide administration was associated with a significant improvement in lung and heart histopathological characteristics and architecture with retraction of LPS-induced inflammatory-infiltration. This was associated with retraction in serum biomarkers of cellular injury of which; LDH, CK-MB, and ALP. Nifuroxazide administration was associated with a significant improvement in both lung and heart oxidative status. Such positive outcomes were underlined by a significant inhibitory effect of nifuroxazide on lung and heart contents of toll-like receptor (4) (TLR4)/the inflammasome NALPR3/interleukin- 1beta (IL-1beta). In conclusion: Nifuroxazide attenuates LPS-induced ALI and myocardial injury via interruption of TLR4/NALPR3/IL-1beta signaling. Thus it can offer a potential approach for attenuation of sepsis in critically ill patients.","Life Sci","Khodir, Ahmed E","Samra, Yara A","Said, Eman","32504751"],"abstract":["Acute lung injury (ALI) and the subsequent multi-system organ failure is a serious health problem with devastating impacts on the health care systems. Indeed, the world has been facing an un-preceded situation in the past couple of months following COVID-19 infestation and the associated high-mortality rates mainly attributed to sepsis and the associated multiple organ failures of particular concern; acute respiratory distress syndrome post lung injury. The current study provides evidence on the ameliorative impact of nifuroxazide, and FDA approved antidiarrheal drug in attenuation of lipopolysaccharide (LPS)-induced ALI and myocarditis when administrated either in prophylactic or curative regimens. Nifuroxazide administration was associated with a significant improvement in lung and heart histopathological characteristics and architecture with retraction of LPS-induced inflammatory-infiltration. This was associated with retraction in serum biomarkers of cellular injury of which; LDH, CK-MB, and ALP. Nifuroxazide administration was associated with a significant improvement in both lung and heart oxidative status. Such positive outcomes were underlined by a significant inhibitory effect of nifuroxazide on lung and heart contents of toll-like receptor (4) (TLR4)/the inflammasome NALPR3/interleukin- 1beta (IL-1beta). In conclusion: Nifuroxazide attenuates LPS-induced ALI and myocardial injury via interruption of TLR4/NALPR3/IL-1beta signaling. Thus it can offer a potential approach for attenuation of sepsis in critically ill patients."],"journal":"Life Sci","authors":["Khodir, Ahmed E","Samra, Yara A","Said, Eman"],"date":"2020-06-07T11:00:00Z","year":2020,"_id":"32504751","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.lfs.2020.117907","keywords":["il-1beta","lps","nalpr3","nifuroxazide","tilr4"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1668892488395390977,"score":41.814217},{"pmid":32224164,"title":"COVID-19 and diabetes: Can DPP4 inhibition play a role?","text":["COVID-19 and diabetes: Can DPP4 inhibition play a role?","Diabetes Res Clin Pract","Iacobellis, Gianluca","32224164"],"journal":"Diabetes Res Clin Pract","authors":["Iacobellis, Gianluca"],"date":"2020-04-01T11:00:00Z","year":2020,"_id":"32224164","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.diabres.2020.108125","topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138492479995905,"score":40.037563}]}